Arun Sanyal MD

Gastroenterology•Richmond, VA

Hepatology & Liver Transplantation

Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine

Join to View Full Profile

1250 E Marshall StRichmond, VA 23298
Phone+1 804-828-6314
Fax+1 804-828-2992

Education & Training

Virginia Commonwealth University Health SystemFellowship, Gastroenterology, 1987 - 1989
Texas Tech University (Amarillo)Residency, Internal Medicine, 1984 - 1987
Maulana Azad Medical CollegeClass of 1981

Certifications & Licensure

VA State Medical License 1986 - 2026
NM State Medical License 1986 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Clinical Trials

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Start of enrollment: 2006 May 01
Completed
Phase 3
Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding Start of enrollment: 2006 Dec 01
Terminated
Phase 3
BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis Start of enrollment: 2008 Aug 01
Completed
Phase 3
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 Start of enrollment: 2009 Dec 02
Completed
Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia Start of enrollment: 2010 Sep 01
Completed
Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT) Start of enrollment: 2011 Feb 01
Terminated
Phase 2
Hepatitis B Research Network Adult Cohort Study Start of enrollment: 2010 Dec 01
Completed
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Start of enrollment: 2011 Oct 01
Completed
Phase 2
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis Start of enrollment: 2012 Dec 01
Withdrawn
Phase 2
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Start of enrollment: 2013 Apr 03
Terminated
Phase 4
Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest Start of enrollment: 2013 Sep 01
Completed
Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis Start of enrollment: 2014 Dec 01
Completed
Phase 2
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Start of enrollment: 2014 Nov 03
Terminated
Phase 2
Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium Start of enrollment: 2013 Jun 01
Completed
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Start of enrollment: 2015 Aug 01
Completed
Phase 2
Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese Start of enrollment: 2018 Apr 01
Not yet recruiting
Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis Start of enrollment: 2019 Apr 16
Completed
Phase 2
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. Start of enrollment: 2019 Sep 23
Completed
Phase 2
Non-Invasive Quantification of Liver Health in NASH (N-QUAN) Start of enrollment: 2020 Aug 05
Recruiting
Not Applicable
Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis Start of enrollment: 2020 Jul 10
COMPLETED
PHASE2
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency Start of enrollment: 2019 Mar 30
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Anti-Tumour Immunity Relies on Targeting Tissue Homeostasis Through Monocyte-Driven Responses Rather Than Direct Tumour Cytotoxicity.
Nicholas Koelsch, Faridoddin Mirshahi, Hussein F Aqbi, Mulugeta Seneshaw, Michael O Idowu
Liver International. 2025-05-01
1 citations
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (...
Zobair M Younossi, Homie Razavi, Michael Sherman, Alina M Allen, Quentin M Anstee
Alimentary Pharmacology & Therapeutics. 2025-05-01
Experimental Models to Investigate PNPLA3 in Liver Steatosis.
Alireza Ramandi, Anna-Mae Diehl, Arun J Sanyal, Ype P de Jong
Liver International. 2025-05-01

Journal Articles

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19
Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Arun J Sanyal, Gregory Huhn, JAMA
The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
HSD17B13 Is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non‐Alcoholic Fatty Liver Disease
Elizabeth K Speliotes, Arun J Sanyal, Hepatology
Mechanisms of NAFLD Development and Therapeutic Strategies
Arun J Sanyal, Mary Rinella, Scott L Friedman, Nature
Recent Advances in Understanding and Managing Non-Alcoholic Fatty Liver Disease
Somaya Albhaisi, Arun Sanyal, F1000Research
Proton Pump Inhibitor Initiation and Withdrawal Affects Gut Microbiota and Readmission Risk in Cirrhosis
Michael Fuchs, Puneet Puri, Mohammad S Siddiqui, Douglas M Heuman, Jasmohan S Bajaj, Arun J Sanyal, Velimir Luketic, Richard K Sterling, Nature
Join now to see all

Lectures

Evaluation of Acute Kidney Injury in a Cirrhotic Patient: HRS and Beyond
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
Future Therapies for NAFLD/NASH
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
Advances in the Management of Cirrhosis and Portal Hypertension
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018

Other

A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-11-20
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-09-10
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2013-04-05
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-06-27
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-12-17
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2012-08-20
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2012-10-18
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2013-04-05
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2013-01-02
Join now to see all

Authored Content

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020

Press Mentions

Phase 3 Trial of Lanifibranor for MASH Completes EnrollmentApril 7th, 2025
Inventiva Announces Completion of Enrollment in the Phase 3 NATiV3 Clinical Trial of Lanifibranor in Patients with MASH and Advanced FibrosisApril 1st, 2025
The Link Between Your Heart Health and MASHJanuary 31st, 2025
Join now to see all